BiotechTube

Tenofovir

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin's Lymphoma, Burkitt's

Conditions

Non-Hodgkin's Lymphoma, Burkitt's

Trial Timeline

Nov 1, 2015 → Sep 1, 2018

NCT ID
NCT02585947

About Tenofovir

Tenofovir is a approved stage product being developed by Gilead Sciences for Non-Hodgkin's Lymphoma, Burkitt's. The current trial status is unknown. This product is registered under clinical trial identifier NCT02585947. Target conditions include Non-Hodgkin's Lymphoma, Burkitt's.

What happened to similar drugs?

5 of 20 similar drugs in Non-Hodgkin's Lymphoma, Burkitt's were approved

Approved (5) Terminated (3) Active (12)
🔄Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
🔄Zoledronic Acid + Vitamin D + Calcium CarbonateNovartisPhase 3
❌Ofatumumab + Rituximab + Ofatumumab + RituximabNovartisPhase 3
🔄rituximab [MabThera/Rituxan] + Standard chemotherapyRochePhase 3
🔄rituximab [Mabthera/Rituxan]RochePhase 3
🔄Chemotherapy (Induction Period) + RituximabRochePhase 3
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00002180Phase 1Completed
NCT02585947ApprovedUNKNOWN

Competing Products

20 competing products in Non-Hodgkin's Lymphoma, Burkitt's

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
LY317615Eli LillyPhase 2
35
LY4584180 + RituximabEli LillyPhase 1
36
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
40
HRS-3738Jiangsu Hengrui MedicinePhase 1
25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
31
ABT-199 + KetoconazoleAbbViePhase 1
29
ABT-199 + RifampinAbbViePhase 1
21
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21
ABT-199 + Rituximab + BendamustineAbbViePhase 1
29
ABBV-291AbbViePhase 1
36
ABT-199AbbViePhase 1
29
AvelumabMerckPhase 1
33